SCHEMBL1521733

SCHEMBL1521733

CNc1ncc2c(n1)N(C)C(=O)N(c1cc(NC(=O)Nc3cc(C(C)(C)C)no3)c(F)cc1C)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.45
BMX P51813 9/20 0.44
TNK2 Q07912 9/20 0.43
MAP4K2 Q12851 9/20 0.43
KDR P35968 3/20 0.43
BRAF P15056 3/20 0.43
KRAS P01116 2/20 0.43
RAF1 P04049 2/20 0.43
MAP2K2 P36507 2/20 0.43
MAP2K1 Q02750 2/20 0.43
BCR P11274 1/20 0.42
RIPK1 Q13546 1/20 0.42
RIPK3 Q9Y572 1/20 0.42
LCK P06239 1/20 0.41
FES P07332 1/20 0.41
RET P07949 1/20 0.41
PDGFRB P09619 1/20 0.41
KIT P10721 1/20 0.41
FGFR1 P11362 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521665 0.94 ABL1 (0.48) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521598 0.91 BRAF (0.42) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521542 0.91 TNK2 (0.49) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521858 0.91 BRAF (0.46) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521615 0.89 FGFR4 (0.42) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521891 0.89 TNK2 (0.46) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521517 0.89 ABL1 (0.44) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521795 0.88 BRAF (0.47) ABL1BMXKDRBRAFKRAS
SCHEMBL1522013 0.87 ABL1 (0.43) ABL1BMXTNK2MAP4K2KDR
SCHEMBL1521760 0.87 TNK2 (0.47) ABL1BMXTNK2MAP4K2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 ABL1 936/4885BMX 947/4885TNK2 119/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ABL1 936/4885BMX 947/4885TNK2 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.